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Anti-malaria drug mefloquine induces motor learning deficits 
in humans
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Mefloquine (a marketed anti-malaria drug) prophylaxis has a high risk of causing adverse events. 
Interestingly, animal studies have shown that mefloquine imposes a major deficit in motor 
learning skills by affecting the connexin 36 gap junctions of the inferior olive. We were therefore 
interested in assessing whether mefloquine might induce similar effects in humans. The main aim 
of this study was to investigate the effect of mefloquine on olivary-related motor performance 
and motor learning tasks in humans. We subjected nine participants to voluntary motor timing 
(dart throwing task), perceptual timing (rhythm perceptual task) and reflex timing tasks (eye-
blink task) before and 24 h after the intake of mefloquine. The influence of mefloquine on motor 
learning was assessed by subjecting participants with and without mefloquine intake (controls: 
n = 11 vs mefloquine: n = 8) to an eye-blink conditioning task. Voluntary motor performance, 
perceptual timing, and reflex blinking were not affected by mefloquine use. However, the 
influence of mefloquine on motor learning was substantial; both learning speed as well as 
learning capacity was impaired by mefloquine use. Our data suggest that mefloquine disturbs 
motor learning skills. This adverse effect can have clinical as well as social clinical implications 
for mefloquine users. Therefore, this side-effect of mefloquine should be further investigated 
and recognized by clinicians.
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et al., 1998; Sohl et al., 2005) and has been found in many brain 
areas such as thalamus, hippocampus, basal ganglia, cerebral cortex, 
olfactory bulb, brainstem, and retina (Condorelli et al., 2000). Cx36 
is highly expressed in the gap junctions of the inferior olive (IO) 
and these electrical synapses are the main source of intra-olivary 
electrical transmissions (De Zeeuw et al., 1995; Condorelli et al., 
2000). The IO gives rise to the climbing fibers projecting to the 
Purkinje cells in the cerebellar cortex and functionally integrates 
sensory information and motor output resulting in well coordi-
nated motor performance, motor learning, and cognitive processes 
(Simpson et al., 1996; Strick et al., 2009).
In mice that were injected with mefloquine in their IO, timing 
deficits of newly learned motor responses were found in an associa-
tive motor learning task (Van Der Giessen et al., 2008), indicating 
the importance of Cx36 gap junctions in the process of learning-
dependent timing. Other studies revealed that the IO is involved in 
the cognitive property of perception of temporal complex rhythmic 
stimuli (Xu et al., 2006; Liu et al., 2008; Wu et al., 2010). The impact 
of mefloquine on the IO and on the olivocerebellar dependent 
behaviors has never been investigated in humans. Results from 
animal studies and the high prevalence of mefloquine associated 
neuropsychiatric adverse events led us to study the hypothesis that 
mefloquine alters olivocerebellar related behaviors in humans.
Therefore, we have investigated the effect of mefloquine on dif-
ferent aspects of motor performance, perceptual timing, and motor 
learning in humans. We examined the influence of mefloquine by 
studying voluntary motor timing (dart throwing task: Smeets et al., 
IntroductIon
The quinolone derivative mefloquine is widely used in the treat-
ment and prophylaxis of malaria in travelers to areas with chlo-
roquine-resistant falciparum malaria (Palmer et al., 1993). In the 
Netherlands mefloquine is generally prescribed when traveling 
for longer than 6 weeks to a malaria endemic region. Mefloquine 
has gained popularity due to its weekly dosing regime and is used 
worldwide by all kinds of civil and military organizations.
A negative effect of mefloquine is that it occasionally causes 
neuropsychiatric adverse events. A number of studies on meflo-
quine tolerability in young and healthy populations have shown 
that mild neuropsychiatric adverse events, like headache, strange 
or vivid dreams, dizziness, anxiety, and sleeplessness, may occur 
in up to 32% of mefloquine users (Schlagenhauf et al., 1996, 2003; 
van Riemsdijk et al., 2002), while more severe neuropsychiatric 
adverse events, like psychosis and bipolar disorder, have also been 
described (Croft and World, 1996; Piening and Young, 1996; Even 
et al., 2001; Toovey, 2009).
Although, it is known that mefloquine interacts with an array of 
protein targets and cellular signaling pathways no studies have been 
performed regarding the nature of the origin of these adverse events 
(Lim and Go, 1985; Gribble et al., 2000; Maertens et al., 2000; Kang 
et al., 2001; Dow et al., 2003; Weiss et al., 2003; Cruikshank et al., 
2004). Mefloquine has been shown to block connexin 36 (Cx36) gap 
junction very potently (Cruikshank et al., 2004; Margineanu and 
Klitgaard, 2006). Cx36 is a plasma membrane protein responsible 
for the formation of gap junctions between neurons (Condorelli 
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of the results with a memory trace. The eye-blink conditioning task 
was performed in a group of participants 24 h after the intake of 
their first mefloquine tablet and in an age- and sex-matched control 
group who did not use mefloquine.
Performance exPeriments
Dart throwing task
In this task participants threw 25 darts at a dartboard and were told 
to aim for the bull’s eye while holding their underarm vertically 
during the course of each throw. They were placed on a standard 
range from the dart board (2 m) and each throw was followed by 
a short pause of 5 s.
Throwing imprecision can be divided in a horizontal and ver-
tical component. The horizontal (E
x
) and vertical deviations (E
y
) 
of each dart from the center of the bull’s eye were determined 
manually (Figure 1B). Under normal conditions, imprecision in 
release timing or throwing speed is not the main source of throw-
ing imprecision, but the imprecision in direction of motion at the 
time of release is considered the main cause of throwing impreci-
sion (Smeets et al., 2002). However, when either speed or timing 
precision is affected by mefloquine, an additional error source is 
introduced that will affect the precision of the dart throw. This error 
source will only affect the vertical component, but not the hori-
zontal component, of the throw (Figure 1A). Therefore, we would 
expect an enhanced variability in the vertical deviation compared 
to the horizontal deviation after the use of mefloquine. The speed 
and timing sensitivity of the dart throw was determined by dividing 
vertical deviation from the target (E
y
) by the total deviation from the 
target (E
y
 + E
x
). The precision of the dart throw was determined by 
dividing the standard deviation of the vertical displacement from 
the target (sdE
y
) by the total standard deviation of the displacement 
from the target (sdE
y
 + sdE
x
).
Rhythm perception task
Functional MRI studies revealed that the IO is activated during 
perception of complex rhythms and perception of a single stimulus 
with unexpected timing, and that the IO is sensitive to the tempo-
ral structure of sensory input (Xu et al., 2006; Liu et al., 2008; Wu 
et al., 2010). In this task participants have to compare successive 
auditory rhythms (Xu et al., 2006). Two successive rhythms were 
generated by two pairs of four tones. Each pair consisted of four 
tones of 500 Hz with a duration time of 5 ms and these tones were 
separated from each other by intervals of 333 ms. The pairs were 
separated by an interval of 2 s (Figure 2A). A rhythm asynchrony 
was introduced in either the first or second four-tone rhythm, 
consequently the other four-tone rhythm became the designated 
standard rhythm. Rhythm asynchrony was achieved by shifting 
the second tone of the rhythm closer to the first (i.e., shortening 
the inter-tone interval). This shortening of the inter-tone inter-
val (perturbation) varied randomly throughout each test block 
between 0, 10, 25, 50, 75, and 100 ms. The task consisted of eight 
blocks and in each block the participants were exposed to all six 
perturbations. For each perturbation we determined the number 
of errors that were made per subject. The 0 ms perturbation served 
as a control of understanding the task and to asses to what extent 
the task was subject to guessing. After each series of two rhythms 
participants were asked whether the rhythms were identical or not. 
2002), perceptual timing (rhythm perception task: Xu et al., 2006), 
reflex timing (reflex blinking: Koekkoek et al., 2002; Smit et al., 
2008), and an associative motor learning task (eye-blink condition-
ing: Koekkoek et al., 2002; Smit et al., 2008).
materials and methods
study PoPulation and exPerimental set uP
We recruited volunteers, who were prescribed mefloquine (Roche, 
USA; the commercial name marketed as Lariam®) for malaria 
prophylaxis at the Travel Clinic Havenziekenhuis in Rotterdam, 
the Netherlands. Written informed consent was obtained from 
the participants or the parents of the participants when they were 
younger than 18 years. The experimental protocol was approved by 
the Erasmus MC Medical Ethics Committee (MEC-2004-205).
Participants who had used mefloquine in the preceding 
2 months, who had risk factors for concentration impairment (e.g., 
use of opioids, hypnotics or tranquilizers during the study period 
or use of alcohol 4 h before testing) or who had illnesses resulting 
in altered motor behavior were excluded from this study. From the 
participants information was collected on gender, weight, height, 
age, weekly physical exercise, and previous mefloquine intake by 
use of a questionnaire (Table 1). The participants were requested to 
take the standard dose of 250 mg mefloquine at the end of dinner, as 
food facilitates mefloquine absorption (Crevoisier et al., 1997). One 
day after the first mefloquine intake, users were carefully reviewed 
for adverse effects (by Thomas A. van Essen, see also Table 1).
The experimental set up consisted of performance tasks: (a) dart 
throwing task, (b) perceptual timing task, and (c) reflex blinking 
task. To test motor learning, the eye-blink conditioning task was 
used. The performance experiments were executed 2–4 days prior 
to the intake of mefloquine (baseline) and 24 h after the intake of 
the first mefloquine tablet. The learning experiments were only per-
formed once per (naïve) subject, in order to prevent  contamination 
Table 1 | Characteristics participants.
Characteristics Performance Learning task Mefloquine 
 task (n = 9) (no mefloquine;  (n = 8) 
  n = 11)
Men/women 6/3 7/4 4/4
Age (years) 40.7 24.3 25.0
Age range (years) 17–67a 20–35a 17–40a
Weight (kg) 74.2 65.5 68.8
Physical exercise 6 (67%) 7 (64%) 5 (63%) 
(≥ 2 × /week)
Adverse events 3 (33%)b – 3 (38%)b
Insomnia 2  1
Head ache 1  1
Abnormal 1  2 
dreams/nightmares
Gender, mean age, age range, mean weight, amount of exercise level, and 
adverse events for each group.
aAge range is different between the motor performance and the motor learning 
participants.
bNumbers do not add up to total adverse events since some participants had 
more than one adverse event.
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tarsal portion of the right upper eyelid (Figure 3A). The signal 
was amplified by a pre-amplifier close to the sensor and further 
amplification could be adjusted per subject. The signal was digi-
tized (1000 Hz) using National Instruments hardware. A custom 
made LabView (National Instruments, Austin, TX, USA) script 
controlled the monitoring of eyelid movement, presentation of the 
stimuli and capturing of data on disk. Via the puff nozzle, an air 
puff (unconditioned stimulus: US) was directed to the cornea close 
to the outer canthus of the eye at a distance of about 15 mm. The 
apparatus served to deliver a 20-ms air-puff with an intensity of 
10–50 PSI at the source. The intensity and duration were manually 
adjusted to elicit a single blink reflex (unconditioned response: UR). 
The participants were explicitly instructed not to guess. Due to the 
involvement of the IO in this task and the temporal structure of the 
task, we would expect more errors in discriminating the rhythms 
after the use of mefloquine.
Reflex blinking
Participants were subjected to reflex blinking and eye-blink condi-
tioning procedures. Eye blinks were recorded with the use of mag-
netic distance measurement technique as described by (Koekkoek 
et al., 2002; Smit et al., 2008). Briefly, a magnetoresistive sensor 
was attached at the rim of the orbit below the right lower eyelid, 
while a small gold plated neodymium magnet was attached to the 
Figure 1 | Dart throwing precision is not affected by the intake of 
mefloquine. (A) Schematic representations of two arms at the time of releasing 
the dart. Vertical throwing precision is more complex than horizontal throwing 
precision; it depends more on the moment of release and the speed of the 
throw. (B) Participants threw darts at a dartboard and for each throw the 
horizontal (Ex) and vertical deviations (Ey) from the center of the bull’s eye were 
determined. (C) The vertical and horizontal precision were not altered by the 
intake of mefloquine (n = 9). Under both conditions, the horizontal component of 
the throw is more precise than the vertical component (*both p < 0.05, n = 9, t 
test). (D) The normalized vertical deviation from the target (n = 9) and (e) the 
normalized standard deviation of vertical deviation from the target (n = 9) were 
not affected by the intake of mefloquine. Blue bars indicate mean + SEM (error 
bar) before mefloquine intake and red bars indicate mean + SEM (error bar) 24 h 
after mefloquine intake.
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ensure that attention deficits and anxiety would not interfere with 
the eye-blink conditioning session (Smit et al., 2008). In the eye-
blink conditioning sessions, participants received eight blocks of 
eight 2 s trials. Each block consisted of one air-puff only trial (US 
only) as described above, one trial in which the tone (CS) was 
presented alone (CS only) and six trials in which tone and air-
puff were paired. In these paired trials the 20 ms air-puff ended 
simultaneously with the 520 ms tone by presenting it with a 500 ms 
delay after onset of the tone (Figure 4A). For each CS only and 
paired trial the presence or absence of a CR was determined. For 
each subject and experiment we calculated the percentage of CRs 
In the reflex blinking sessions 15 blinks were randomly evoked in 1 s 
trials each. For each reflex blink three temporal aspects, the onset, 
peak time velocity, and peak time amplitude were determined. The 
onset of the blink is the time between the start of the US and the 
start of the eyelid movement, the peak time velocity is the time 
between the start of the US and the moment that the eyelid reaches 
the maximal velocity (which is determined after differentiating the 
eyelid trace), and the peak time amplitude is the time between the 
start of the US and the moment that the eyelid reaches the maximal 
amplitude (Figure 3A).
motor learnIng: eye-blInk condItIonIng
Eye-blink conditioning is an associative learning task 
(Gormezano et al., 1962), in which a reflex blink (induced by 
US) is associated to a tone (conditioned stimulus: CS). Repetitive 
paired presentation of the CS with the US results in the gen-
eration of a conditioned response (CR), a closure of the eye-
lid upon presentation of CS (Figure 4A). The olivocerebellar 
system is involved in this conditioning of the eyelid response 
(Medina et al., 2000).
For this task the participants were equipped with a headphone, 
video goggles (Logitech, USA), and a puff nozzle. The headphone 
and video goggles provided additional entertainment in order to 
Figure 2 | Perception of complex rhythms is not impaired by the intake 
of mefloquine. (A) Schematic representation of the rhythm perception task. 
Two rhythms consisting of four tones are separated by a pause of 2 s. One of 
the rhythms has a timing perturbation of the second tone. This perturbation 
varies in size (0, 10, 25, 50, and 100 ms). The subject has to determine 
whether the rhythms are identical or different. (B) The ability to distinguish 
complex rhythmic stimuli as a function of perturbation length (ms) is reflected 
in the number of errors made per type of perturbation. Blue squares indicate 
mean % of errors ± SEM (error bars) before mefloquine intake and red 
squares indicate mean % of errors ± SEM (error bars) 24 h after mefloquine 
intake (n = 9).
Figure 3 | reflex blinking is not affected by the intake of mefloquine. (A) 
Left panel: Schematic drawing of eye-blink recording system. A gold plated 
neodymium magnet was attached to the edge of the upper eyelid (red circle), 
while a magnetoresistive sensor was attached at the edge of the orbit below 
the right lower eyelid (green circle). A blink was induced by a small air-puff 
(unconditioned stimulus: US). An increased magnetic force is detected by the 
sensor during closure of the eyelid. Right panel: eyelid movement recording of 
an unconditioned response (UR). Three temporal aspects of the reflex blink 
were determined: the onset, peak time velocity and peak time amplitude (red 
arrows). Figure is adopted from Smit et al. (2008). (B) Histogram of eye-blink 
timing parameters before (blue bars) and 24 h after the intake of mefloquine 
(red bars). (C) Histogram of standard deviations of the measured eye-blink 
timing parameters before (blue bars) and 24 h after the intake of mefloquine 
(red bars). Histograms show mean and SEM (n = 9).
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speed) of the model. The goodness of fit was indicated by R2 values. 
All mean values were accompanied by standard error of the mean 
(SEM) unless stated otherwise.
results
In the study period of July 2009 to April 2010, 28 individuals 
were included. Nine participants volunteered for the perform-
ance experiments and 19 for the motor learning experiments (8 
used mefloquine; 11 individuals served as control participants [no 
mefloquine use]). Table 1 summarizes the general characteristics of 
the individuals participating in the performance and motor learn-
ing experiments. Six participants reported adverse events after the 
intake of mefloquine (see Table 1).
Performance of voluntary motor tImIng, PercePtual tImIng, 
and reflex tImIng Is not affected In mefloquIne users
To find out whether mefloquine leads in humans to deficits in 
olivocerebellar related performances, we tested our partici-
pants before and after the intake of mefloquine (i.e., off and on 
medication), using specific tasks in which the IO is thought to 
be involved.
Voluntary motor timing was assessed by a dart throwing task. 
Throwing imprecision can be divided in a vertical and horizontal 
component. Imprecision in release timing or throwing speed is more 
reflected in the vertical deviation than in the horizontal deviation to 
the target (Figure 1A). Our participants revealed a significant larger 
vertical deviation than horizontal deviation under both conditions 
(Figure 1C, meflo: p = 0.01, no meflo: p = 0.01, t test), indicating 
the more complex control of the vertical component over the hori-
zontal component of the throw. The vertical deviation as well as 
the horizontal deviation was not affected by the use of mefloquine 
(Figure 1C, p = 0. 47 and p = 0.73 respectively, n = 9, t test). In order 
to correct for non-specific inter-trial variability, we normalized the 
vertical deviation by the total deviation of each throw. These nor-
malized vertical deviations did not reveal a significant difference 
(Figure 1D, p = 0.45, n = 9, t test). Neither did the normalized 
variation in the vertical deviation, which is an indicator for vertical 
throwing precision (Figure 1E, p = 0.34, n = 9, t test).
Since the IO has been suggested to play a role in the perception 
of complex rhythms (Xu et al., 2006), we investigated whether a 
rhythm perception task in mefloquine users would result in reduced 
ability to distinguish between rhythms (Figure 2A). No significant 
differences were found with respect to the number of errors made 
per perturbation between the two conditions (Figure 2B). The 
25 ms perturbation yielded the largest difference, although not 
significant (p = 0.25, n = 9, t test).
The effect of mefloquine on an involuntary motor performance 
task was investigated by studying the reflex blink (Figure 3A). Reflex 
blinks obtained before and after the intake of mefloquine were ana-
lyzed kinetically. The onset, the peak time velocity and the peak time 
amplitude did not reveal a significant difference between partici-
pants “off” mefloquine compared to “on” mefloquine (Figure 3B, 
p = 0.78, n = 9, t test). The precision in timing of the eye-blink was 
investigated by testing the standard deviation of these parameters. 
Although, the standard deviations were all larger when the par-
ticipants were under the influence of mefloquine, they were not 
significantly larger (Figure 3C, p = 0.59, n = 9, t test).
within the blocks and as a whole. The eight blocks were preceded 
by the first block, called block 0, during which participants were 
presented tone-only trials. In this block, we confirmed that the 
participants did not yet learned the ability to make a conditioned 
eye-blink response.
statIstIcal analyses
With regard to the performance experiments, all comparisons were 
done with paired, two-tailed t test. For the learning experiments 
(i.e., eye-blink conditioning), we used the unpaired, two-tailed t 
test. Furthermore, we fitted this learning data set with the following 
learning curve: the exponential function y = a − a. exp−x/b, where y 
is the percentage of CRs, x the block number, and a and b are the 
learning coefficients (a represents learning capacity and b learning 
Figure 4 | eye-blink conditioning is impaired by the intake of mefloquine. 
(A) Left panel: Schematic drawing of eye-blink conditioning. Right panel: eyelid 
movement recording of a response before (UR: unconditioned response) and 
after conditioning (CR: conditioned response). (B) Example of 48 eyelid 
recordings of a control subject (i.e., no mefloquine use; left panel) and a 
mefloquine user (right panel) during the acquisition. The conditioned stimulus 
(CS) is indicated by the light-blue bar, ranging from 500 to 1020 ms. The 
unconditioned stimulus (US) is indicated by the vertical black line, ranging from 
1000 to 1020 ms. (C) Histogram of the total number of CRs in % observed in 
control subject (blue, n = 11) and mefloquine users (red, n = 8; *p < 0.05, t test). 
(D) The average percentages of CRs in each acquisition block is plotted for the 
control group (blue squares) and mefloquine group (red squares). Learning 
curves were used to fit both data sets (R Rcontrol
2
mefloquine
2and= =0 98 0 87. . ).
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The training process in these animals was slowed down  substantially, 
but they revealed no impaired general motor performance (Kistler 
et al., 2002; Van Der Giessen et al., 2008) similar to our findings in 
humans. The lack of effect of mefloquine on general performance 
is most likely due to the specific function of Cx36 within the IO. 
Blocking Cx36 by mefloquine does not affect the performance, it 
makes the performance only unadjustable. In order to affect these 
performances other mechanisms within the IO need to be altered 
(Rondi-Reig et al., 1997; Welsh, 1998).
With regard to our experimental design, the question arises 
whether a single dose of mefloquine is capable of altering brain 
functions. Mefloquine has no problem crossing the blood–brain 
barrier (Baudry et al., 1997) and there is evidence that mefloquine 
can accumulate in the brain (Barraud de Lagerie et al., 2004). This 
is, for instance, supported by the observation of a higher risk of 
neuropsychiatric adverse events in the first days after first meflo-
quine intake (Schlagenhauf et al., 1996, 2003; van Riemsdijk et al., 
2002), suggesting a direct effect of mefloquine on the brain. Some 
of these neuropsychiatric adverse events were also observed in our 
mefloquine using participants (Table 1). Furthermore, the reported 
IC
50
 of mefloquine for Cx36 is 0.3 μM (Cruikshank et al., 2004) and 
this is much smaller than the mefloquine blood level concentration 
achieved with one dosage of 250 mg mefloquine (Pennie et al., 
1993), indicating that the level of mefloquine in the brain is high 
enough to alter brain functions.
Of course, one could argue that the altered brain function 
associated with mefloquine might be caused by mechanisms 
other than interference with Cx36 gap junction coupling. 
However, the IC
50
 values for mefloquine inhibiting ATP-sensitive 
potassium channels (IC
50
 = 3 μM), L-type calcium channels 
(IC
50
 ≈ 10 μM), delayed rectifier channels (IC
50
 = 1 μM), and 
volume- (IC
50
 = 1 μM) and calcium-activated chloride chan-
nels (IC
50
 = 3 μM) are all higher than those required for Cx36 
blockade (Coker et al., 2000; Gribble et al., 2000; Maertens et al., 
2000; Kang et al., 2001). So far, Cx36 gap junctions are the most 
mefloquine-sensitive molecules in the brain and the mefloquine 
blocking effect in the IO will lead to motor learning deficit (Van 
Der Giessen et al., 2008).
Finally, one could also suggest that the present findings might be 
explained by a confounding involvement of other Cx36 containing 
brain areas apart from the IO. Despite the fact that for all the tasks 
used in this study the involvement of the IO is necessary (Rondi-
Reig et al., 1997; Xu et al., 2006; Van Der Giessen et al., 2008), we 
cannot directly exclude a possible role of other Cx36 containing 
brain areas. It is, though, noteworthy that an altered attention due to 
mefloquine might have affected the dart throwing and the rhythm 
perception task; it cannot explain the results on eye-blink and eye-
blink conditioning tasks, because not being aware of the stimuli 
does not prevent eye blinking or eye-blink conditioning (Smith 
et al., 2005). Thus, the most likely explanation for our results is the 
selective blocking of Cx36 gap junctions in the IO.
The demonstration that mefloquine, a marketed anti-malarial 
drug, imposes a deficit in motor learning capabilities in man might 
come as a surprise in the field of adverse events of malaria prophy-
laxis and treatment. Although this adverse effect is not defined on 
direct clinical grounds (i.e., people do not report the adverse effect 
reduced motor learning as a result of mefloquine usage), it can have 
In all performance tasks the variation was more closely examined 
with the coefficient of variation (CV). The resulting CVs were not 
significantly different either (unpublished observations). Taken 
together, these results show that mefloquine has no influence on 
these three different IO-related performance tasks.
eye-blInk condItIonIng Is affected In mefloquIne users
To investigate whether the use of mefloquine leads to motor learn-
ing deficits in humans, we tested mefloquine users and control 
participants (i.e., no mefloquine use) using an eye-blink condition-
ing task (Figure 4A).
Compared to the control participants, mefloquine users showed 
a significant lower number CRs that were acquired during training 
and after training (Figures 4B,C, p = 0.02, control participants: 
n = 11 and mefloquine users: n = 8, t test). The percentage of CRs 
was on average 74.0 ± 4.7% in the control group and 46.8 ± 11.0% 
in the group of mefloquine users. The learning curves of the meflo-
quine group and the control group are plotted in Figure 4D. Before 
the task started, it was confirmed that volunteers did not respond 
to the tone and did respond to the US with an UR. Therefore, in 
block 0 no conditioned blinking has been observed. In blocks 1, 2, 
4, 5, and 6 the number of CRs was significantly lower in the group 
of mefloquine users compared to the control group (respectively 
p = 0.03, 0.01, 0.01, 0.04, and 0.03, t test), whereas blocks 3, 7, and 
8 did not reveal significantly difference (respectively p = 0.14, 0.14, 
and 0.08, t test). Curve fitting the data of both groups resulted 
in well-associated learning curves (Rcontrol
2 = 0 98. , p < 0.01 and 
Rmefloquine
2 = 0 87. , p < 0.01). The fitted learning curve generated two 
learning coefficients: a and b. The learning coefficient a represents 
learning capacity, whereas the learning coefficient b represents learn-
ing speed. The coefficients a and b of the learning curves were both 
significantly different between the control group and the group 
of mefloquine users (control: a = 84.7 ± 0.7 and b = 1.53 ± 0.05 
vs mefloquine: a = 70.8 ± 7.2 and b = 3.96 ± 0.71, both p < 0.05, t 
test). Mefloquine users learned this task 2.6 times slower than the 
participants that did not use mefloquine and their learning capacity 
was also reduced by 16% compared to the non-users. The average 
onset latency of the CRs was similar in the mefloquine group and 
control group (control: 877 ± 14.8 ms vs mefloquine: 906 ± 16.6 ms, 
p = 0.23, t test). UR onset across groups did not differ either (con-
trol: 1062 ± 6.1 ms vs mefloquine: 1075 ± 4.5 ms, p = 0.13, t test), 
excluding that possible deficits in reflex pathways can contribute 
to the observed reduced motor learning. Conclusively, these data 
show that the use of mefloquine affects motor learning.
dIscussIon
In this study we investigated the possibility that mefloquine induces 
deficits in olivocerebellar related behaviors in young and healthy volun-
teers. We show that mefloquine has no effect on dart throwing, rhythm 
perception and reflex blinking, but has an effect on the conditioning 
of eye-blink responses to a tone (associative learning). In this learning-
dependent motor task, mefloquine users were impaired in their learn-
ing speed as well as in their learning capacity. Mefloquine reduced their 
learning speed by 2.6 times and their learning capacity by 16%.
Animal studies in which mefloquine was injected in the IO and 
studies on Cx36-deficient mice have shown comparable motor 
learning problems (Frisch et al., 2005; Van Der Giessen et al., 2008). 
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clinical relevance. For example, the use of mefloquine may limit the 
speed and capacity to rehabilitate motor functions after traumatic 
injuries. Moreover, knowledge of this effect is also relevant for civil 
and military organizations that detach people to malaria endemic 
regions where they have to rely heavily on fine-tuning their motor 
skills or learn new motor skills. Therefore, this adverse effect should 
be further investigated and recognized by clinicians.
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